

Approach to Internal Medicine

A Resource Book for Clinical
Practice

David Hui · Alexander A. Leung ·
Christopher Ma *Editors*

Fifth Edition



Springer

Editors

David Hui
The University of Texas MD
Anderson Cancer Center
Houston, TX
USA

Alexander A. Leung
University of Calgary
Calgary, AB
Canada

Christopher Ma
University of Calgary
Calgary, AB
Canada

ISBN 978-3-030-72979-0 ISBN 978-3-030-72980-6 (eBook)
<https://doi.org/10.1007/978-3-030-72980-6>

© The Editor(s) and The Author(s), under exclusive license to Springer Nature
Switzerland AG 2022

This work is subject to copyright. All rights are solely and exclusively licensed by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, expressed or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This Springer imprint is published by the registered company Springer Nature Switzerland AG
The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland

Interstitial Lung Disease

Raghu et al. *AJRCCM* 2018;198(5)

DIFFERENTIAL DIAGNOSIS

PRIMARY (idiopathic)—usual interstitial pneumonia (UIP), respiratory bronchiolitis-associated interstitial lung disease (RBILD), desquamate interstitial pneumonia (DIP), acute interstitial pneumonia (AIP), non-specific interstitial pneumonia (NSIP), lymphoid interstitial pneumonia (LIP), cryptogenic organizing pneumonia (COP)

SECONDARY ★DICE★

- **DRUGS**—chemotherapy (bleomycin), sulfa, penicillin, sulfonyleurea, gold, penicillamine, phenytoin, amiodarone, nitrofurantoin
- **INFILTRATIVE**—lymphangitic carcinomatosis, sarcoidosis
- **INFECTIONS**—TB, histoplasmosis, coccidioidomycosis
- **INFLAMMATORY**—rheumatoid arthritis, SLE, scleroderma, ankylosing spondylitis, myositis
- **CONGESTIVE HEART FAILURE**
- **ENVIRONMENT**—**organic dust** (hypersensitivity pneumonitis), **inorganic dust** (asbestos, silica, beryllium, coal worker's pneumoconiosis)
- **EOSINOPHILIA-ASSOCIATED PULMONARY INFILTRATES**—allergic bronchopulmonary aspergillosis (ABPA), parasitic, drugs
- **ETC**—pulmonary histiocytosis X, idiopathic pulmonary hemosiderosis, lymphangioleiomyomatosis, radiation

CLINICAL FEATURES

HISTORY—dyspnea (duration, progression), cough, hemoptysis, wheezes, chest pain, impaired exercise tolerance, occupational history (details of all previous jobs, exposure to gases or chemicals

CLINICAL FEATURES (CONT'D)

particularly important), environmental exposure (home setting, air-conditioning, pets, hobbies), rash, joint swelling, past medical history (smoking), medications, family history

PHYSICAL—vitals (tachypnea, hypoxemia), cyanosis, clubbing (idiopathic pulmonary fibrosis, asbestosis, rheumatoid lung, fibrosing NSIP), decreased chest expansion, crackles (fine), wheezes, cor pulmonale. Note that sarcoidosis and silicosis may have a normal lung examination

Related Topics

Allergic Bronchopulmonary Aspergillosis (p. 4)
Restrictive Lung Disease (p. 26)
Rheumatoid Arthritis (p. 297)
Sarcoidosis (p. 483)
Tuberculosis (p. 267)

INVESTIGATIONS

BASIC

- **LABS**—CBC, ANA, RF, anti-CCP antibody, anti-Scl-70, anticentromere antibody, anti-Jo-1 antibody
- **IMAGING**—CXR, CT chest (high resolution), echocardiogram (if suspect pulmonary hypertension)

ABG

PFT

SPECIAL

- **BIOPSY**—bronchoscopy (transbronchial biopsy), referral to thoracic surgery for VATS lung biopsy

DIAGNOSTIC ISSUES

CHARACTERISTIC CXR PATTERNS FOR INTERSTITIAL LUNG DISEASE

- **UPPER LOBE PREDOMINANCE**—sarcoidosis, hypersensitivity pneumonitis, pneumoconiosis, silicosis, histiocytosis X, PJP, ankylosing spondylitis, ABPA, TB
- **LOWER LOBE PREDOMINANCE**—idiopathic pulmonary fibrosis, asbestosis, rheumatoid arthritis, scleroderma, drugs
- **BILATERAL HILAR/MEDIASTINAL ADENOPATHY WITH INTERSTITIAL INFILTRATES**—sarcoidosis, berylliosis, lymphangitic carcinomatosis, TB, fungal, lymphoma
- **EGGSHELL CALCIFICATION OF HILAR/MEDIASTINAL LYMPH NODES**—silicosis (other pneumoconiosis), TB, fungal
- **CALCIFIED PLEURAL PLAQUES**—asbestos
- **PLEURAL EFFUSIONS WITH INTERSTITIAL INFILTRATES**—HF, lymphangitic carcinomatosis, rheumatoid arthritis, SLE

MANAGEMENT

TREAT UNDERLYING CAUSE—**sarcoidosis** (if stage \geq II or symptomatic, consider glucocorticoids for several months with tapering dose)

LUNG TRANSPLANT

SPECIFIC ENTITIES

IDIOPATHIC PULMONARY FIBROSIS (IPF)

- **PATHOPHYSIOLOGY**—unknown. Fibrotic rather than inflammatory process; associated with histopathological and/or radiological pattern of usual interstitial pneumonia (UIP)
- **DIAGNOSIS**—high resolution CT chest may show patterns of UIP (honeycombing, interlobular septal thickening, traction bronchiectasis, peripheral, sub-pleural, lack of ground glass pattern), probable UIP, indeterminate for UIP or alternate diagnosis; bronchoscopy (to rule out other causes, mostly infectious); consider open lung biopsy if CT is not consistent with above
- **TREATMENTS**—multidisciplinary discussion for diagnosis and treatment. Referral for lung

SPECIFIC ENTITIES (CONT'D)

transplantation should be done early; consider palliative care involvement, pulmonary rehabilitation, vaccinations, supplemental oxygen; consider pirfenidone or nintedanib for mild to moderate disease. Systemic steroids ineffective

HYPERSENSITIVITY PNEUMONITIS

- **PATHOPHYSIOLOGY**—inhaled organic antigens \rightarrow immune response \rightarrow acute, subacute, or chronic granulomatous pneumonia
- **DIAGNOSIS**—**major criteria** (compatible symptoms, antigen exposure, imaging findings, lavage lymphocytosis, histologic findings [poorly formed granulomas], re-exposure triggers symptoms); **minor criteria** (bilateral crackles, \downarrow DLCO, hypoxemia). Combination of major and minor criteria will help raise suspicion of hypersensitivity pneumonitis. Serology may be helpful
- **TREATMENTS**—cessation of exposure, steroids

ORGANIZING PNEUMONIA (OP)—previously known as bronchiolitis obliterans organizing pneumonia (BOOP)

- **CAUSES**—**idiopathic** (80%, also known as cryptogenic organizing pneumonia [COP]), **post-infectious** (CMV, influenza, adenovirus, *Chlamydia*), **drugs** (amiodarone, bleomycin, gold, sulfasalazine, cephalosporin, cocaine), **connective tissue disease** (RA, SLE, scleroderma, Sjögren syndrome, dermatomyositis), **immunologic** (essential mixed cryoglobulinemia), **transplantation** (bone marrow, lung, kidney), **malignancy** (MDS, lymphoproliferative diseases, radiation)
- **CLINICAL FEATURES**—about 50% of cases preceded by viral-like respiratory infection. Symptoms include dyspnea on exertion, persistent non-productive cough, and weight loss
- **DIAGNOSIS**—characteristic findings on CXR and CT chest include bilateral, diffuse, ill-defined peripheral alveolar opacities distributed peripherally. PFT shows mainly restrictive lung disease pattern
- **TREATMENTS**—*prednisone* 1 mg/kg PO daily for several months with slow taper